Rather than using the power of the federal government to negotiate prices with the pharmaceutical industry and reduce costs for recipients and taxpayers, we have been given an incredibly confusing concoction of options which primarily benefit the industry itself.
We're happy to get the work done, but we just need to negotiate and sort out the costs.